360 filings
Page 2 of 18
8-K
4j403sf 7wlv
28 Feb 22
Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance
12:00am
8-K
c7gkwoc6
14 Dec 21
Departure of Directors or Certain Officers
4:05pm
8-K
58qv7wu0unzp
4 Nov 21
Dynavax Reports Third Quarter 2021 Financial Results
4:50pm
8-K
6cpmpgek quy
21 Oct 21
Departure of Directors or Certain Officers
4:31pm
8-K
enh t8qs9sgmmhvtlke
4 Aug 21
Dynavax Announces Second Quarter 2021 Financial Results
4:06pm
8-K
2s22z98hif
7 Jul 21
Entry into a Material Definitive Agreement
4:05pm
8-K
hm1lin nwznrl2
1 Jul 21
Entry into a Material Definitive Agreement
4:17pm
8-K
lg45kaxwbc1t feiy0up
24 Jun 21
Departure of Directors or Certain Officers
4:10pm
8-K
8tyvp3xrg7 24tzh
2 Jun 21
Departure of Directors or Certain Officers
4:50pm
8-K
dk1wf
26 May 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:05pm
8-K
53wwoa8
13 May 21
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
4:38pm
8-K
6x0x4 qkjui
6 May 21
Dynavax Announces First Quarter 2021 Financial Results
4:08pm
8-K
320ys2 a9lmp0
5 May 21
Entry into a Material Definitive Agreement
8:57am
8-K
8342 deao9jx7sj
6 Apr 21
Other Events
4:11pm
8-K
mx9uh2uzabsegc5zwp
25 Feb 21
Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
4:07pm
8-K
babid
19 Feb 21
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
2:07pm
8-K
qaxzmrq
1 Feb 21
Entry into a Material Definitive Agreement
8:10am
8-K
thjpv
21 Jan 21
Departure of Directors or Certain Officers
9:01am
8-K
02tx0
12 Jan 21
Departure of Directors or Certain Officers
4:24pm
8-K
k7bvs9n0ci2s6d1
7 Jan 21
Other Events
4:10pm